



The Journal of Rheumatology

VOLUME 46: NO. 8

jrheum.org

AUGUST 2019

Editorials

- Assessment of Enthesitis in Psoriatic Arthritis**
P.S. Helliwell 869
- Treatment of Lyme Arthritis** *A.C. Steere* 871

Rheumatoid Arthritis

- Effect of Concomitant DMARD and MTX Administration Route on Biologic Treatment Durability in RA: OBRI Cohort Results** *A.N. Lau, J.C. Thorne, M. Movahedi, et al, and the OBRI Investigators* 874
- MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic DMARD in RA**
C. Peterfy, J. DiCarlo, P. Emery, et al. 887

Spondylitis

- Clinical Characteristics of Patients with SpA in Japan in Comparison with Other Regions of the World**
M. Kishimoto, K. Yoshida, N. Ichikawa, et al 896

Psoriatic Arthritis

- Ultrasonographic and Clinical Assessment of Peripheral Enthesitis in Patients with PsA, Psoriasis, and Fibromyalgia Syndrome: The ULISSE Study**
P. Macchioni, C. Salvarani, N. Possemato, et al 904

Systemic Lupus Erythematosus

- Improvement of Outcomes in Patients with Lupus Nephritis: Management Evolution in Chinese Patients from 1994 to 2010**
S.J. Shao, J.H. Hou, G.T. Xie, et al 912

Systemic Sclerosis

- Economic Burden among Commercially Insured Patients with SSc in the United States**
Z. Zhou, Y. Fan, W. Tang, et al. 920

Vasculitis

- Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis**
G. Tomasson, J.T. Farrar, D. Cuthbertson, et al, for the Vasculitis Clinical Research Consortium 928

Myositis

- Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease**
T. Fujisawa, H. Hozumi, H. Yasui, et al 935

Pediatric Rheumatology

- Pediatric Antibiotic-refractory Lyme Arthritis: A Multicenter Case-control Study**
D.B. Horton, A.J. Taxter, A.L. Davidow, B. Groh, D.D. Sherry, C.D. Rose 943
- Intraarticular Glucocorticoid Injection as Second-line Treatment for Lyme Arthritis in Children**
D.B. Horton, A.J. Taxter, A.L. Davidow, B.P. Groh, D.D. Sherry, C.D. Rose 952

Images in Rheumatology

- A Great Masquerader: Chronic Active Epstein-Barr Virus for the Rheumatologist**
A. Chhabra, R. Alyazidi, A. Human 960

OMERACT 2018: International Consensus Conference on Outcome Measures in Rheumatology, Terrigal, Australia, May 2018

- Introduction**
L. March, B. Richards, M. Gill, et al. 962

Free online via JRheum Full Release option

Contents continued on page xii

Workshops and Special Sessions

The OMERACT Core Domain Set for Clinical Trials of Shoulder Disorders <i>S. Ramiro, M.J. Page, S.L. Whittle, et al</i>	969
Uptake of the OMERACT-OARSI Hip and Knee OA Core Outcome Set: Review of RCT from 1997 to 2017 <i>T.O. Smith, M. Mansfield, G.A. Hawker, et al</i>	976
The OMERACT-OARSI Core Domain Set for Measurement in Clinical Trials of Hip and/or Knee OA <i>T.O. Smith, G.A. Hawker, D.J. Hunter, et al</i>	981
PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess PsA-specific Health-related Quality of Life in Clinical Trials <i>A.M. Orbai, R. Holland, Y.Y. Leung, et al</i>	990
Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 PsA Workshop Report <i>A. Duarte-García, Y.Y. Leung, L.C. Coates, et al</i>	996
Establishing an Updated Core Domain Set for Studies in JIA: A Report from the OMERACT 2018 JIA Workshop <i>E.M. Morgan, J.E. Munro, J. Horonjeff, et al</i>	1006
Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology <i>L.J. Maxwell, D.E. Beaton, B.J. Shea, et al</i>	1014
OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies <i>M. Boers, D.E. Beaton, B.J. Shea, et al</i>	1021

Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology <i>D.E. Beaton, L.J. Maxwell, B.J. Shea, et al</i>	1028
The Third Biennial 2018 OMERACT First-time Participant Program: A Qualitative and Quantitative Study <i>V.S. Sloan, S. Grosskleg, G. Wells, J.A. Singh</i>	1036
Consensus Building in OMERACT: Recommendations for Use of the Delphi for Core Outcome Set Development <i>S. Humphrey-Murto, R. Crew, B. Shea, et al</i>	1041
The OMERACT Emerging Leaders Program: The Good, the Bad, and the Future <i>C.A. Flurey, P.S. Tugwell, R.J. Black, et al</i>	1047
Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for RCT <i>K.M. Andersen, J.T. Cheah, L. March, et al</i>	1053

Letter

Thirty Years of Followup in 3 Patients with Familial Polyarteritis Nodosa due to Adenosine Deaminase 2 Deficiency <i>J. Liebowitz, D.B. Hellmann, O. Schnappauf</i>	1059
---	------

Meetings	vi
---------------------------	----